Evidence Hub

Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial

J. Pettus, Dominic N. Reeds, T. Cavaiola, S. Boeder, M. Levin, Gary Tobin, E. Cava, Dung Thai et al.

Diabetes, obesity and metabolism, 2018

21 participants · 60 citations

Abstract

The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD‐477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70‐mg dose of REMD‐477 (half‐life 7‐10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD‐477 than with placebo (P = .02). Continuous glucose monitoring during post‐treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower (P 180 mg/dL) was ~40% lower (~4 h/d) (P = .001) in the REMD‐477 group than in the placebo group, without a difference in percent time‐in‐hypoglycaemic‐range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 21 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free